Hillebrand, Rajani Rangray, Hayden Smith Limited data exist concerning the clinical disposition of US patients with selleck compound chronic hepatitis C infection (CHC), including the reasons for lack of antiviral therapy. METHODS: The electronic health records of confirmed chronic hepatitis C (CHC) patients in four large US health systems were reviewed from the time of diagnosis through the end of 201 1. Demographic and laboratory data were collected electronically, and trained research abstractors collected history of past or present antiviral therapy. For patients not currently on therapy at the end of 201 1, the

abstractor selected the primary reason from a pre-defined list, which included whether

the patient a) had followed up in the clinic after initial confirmation of CHC infection, b) had been evaluated for therapy; and c) had virologic Selleckchem Pirfenidone confirmation of SVR (or was described by a specialist in hepatology, gastroenterol-ogy, or infectious disease as having achieved an SVR), as well as other reasons for not being on treatment. In addition, FIB-4 scores were computed based on most recently available ALT, AST, and platelet count for each patient. RESULTS: There were 4,271 CHC patients abstracted through the end of 201 1 that were still alive and being followed. Median age was 57 years, 57% were male, 29% were black, and 97% were insured. 543 (12.7%) had previously achieved an SVR and 1 10 (2.6%) were currently on therapy. Of the remaining 3618 patients, 12% had never been followed up within the health care system despite clinical confirmation of their CHC status. The majority, 55%, were not being treated either because of absolute contraindications to current therapy or because either the patient or physician were waiting for newer therapies. An additional 12% of patients had chosen not to start therapy despite provider recommendation to begin treatment. Median FIB-4 score was 1.63 among the treatment naïve patients, this website 1.25 among patients that had achieved an SVR, and 1.93 among the previously treated patients who had not

achieved an SVR. Median FIB-4 scores were consistently lower across all age groups among patients who had achieved SVR compared to those who had not. CONCLUSIONS: These results confirm that only a small proportion of US CHC patients within health care systems who were still being followed at the end of 201 1 had achieved an SVR with available antiviral regimens. Despite confirmation of infectivity, 12% had never been further evaluated. Based on FIB-4, patients who achieved SVR had lower degrees of fibrosis than patients who were untreated. Major reasons for lack of current treatment included contraindications to current therapies and patient/provider preference to await newer treatment options. Disclosures: Stuart C.